World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

Cision PR Newswire by Cision PR Newswire
June 5, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates 

The dataset was shared as part of a poster presentation at the American Diabetes Association’s (ADA) 86th Scientific Sessions

BOULDER, Colo., June 5, 2026 /PRNewswire/ — Ambrosia Biosciences Inc. (“Ambrosia”), today announced preclinical data supporting its small molecule GLP-1 receptor agonist development candidate, AMB-702, in a poster presentation at the American Diabetes Association’s (ADA) 86th Scientific Sessions.


Ambrosia Biosciences (PRNewsfoto/Ambrosia Biosciences)

AMB-702 demonstrated sustained weight loss and reduction in food intake over 7 days of daily dosing in a lean non-human primate (NHP) model. In a head-to-head comparison, AMB-702 achieved placebo-adjusted mean weight loss of 12.6% after 7 days of daily dosing at 2 mg/kg, compared to 5.4% for orforglipron at the same dose and formulation. AMB-702 also demonstrated improved glycemic control and enhanced insulin secretion in an intraperitoneal glucose tolerance test (IPGTT) in a humanized GLP-1 receptor mouse model.

Additional data showing improved performance in a clinic-ready formulation and additional comparator studies will also be presented.

“These data are consistent with AMB-702’s improved in vitro and PK profile, including superior target coverage over 24 hours, improved cell potency, flatter peak-to-trough and reduced plasma protein binding. The superiority of AMB-702 in lean NHP models underscores its differentiation and the potential of next-generation molecules for obesity and metabolic diseases,” said Patrice Lee, Ph.D., President, R&D.

“Importantly, AMB-702 has the potential for lower effective human dosing, which we believe could substantially improve scalability. We look forward to advancing AMB-702 into the clinic early next year,” said Nick Traggis, CEO. “Beyond AMB-702, Ambrosia’s next-generation, small molecule pipeline also includes a once-weekly GLP-1 receptor agonist, a GIP receptor antagonist, and an amylin receptor agonist, all enabling a significant opportunity for combination therapies.”

About Ambrosia Biosciences Inc.

Ambrosia Biosciences Inc. is a privately held drug discovery company developing next-generation oral small molecule therapies for obesity and other metabolic disorders. By integrating structurally-enabled drug design with in-house medicinal chemistry and biology capabilities, Ambrosia is advancing a complementary pipeline of differentiated therapies. The Company aims to expand access to cardiometabolic therapies that improve the patient experience while reducing the cost and complexity of treatment. For more information, please visit www.ambrosiabiosciences.com.

Forward-Looking Statement
This press release may contain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements. Words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements.

These forward-looking statements include, among others, statements regarding Ambrosia’s goals and strategic plans. Such statements are based on management’s current expectations and involve risks, uncertainties and assumptions. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Moreover, Ambrosia operates in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for its management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. Ambrosia undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

Investor & Media Contact:

Ambrosia Biosciences
Andrea Flynn, Ph.D.
Chief Business Officer
PR@ambrosia.health

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ambrosia-biosciences-announces-preclinical-data-supporting-differentiated-profile-of-amb-702-its-novel-small-molecule-glp-1-receptor-agonist-development-candidate-302793162.html

SOURCE Ambrosia Biosciences

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • Great American Media Continues to Raise the Standard for Christmas Entertainment with New Original Series Starring Candace Cameron Bure and Cameron Mathison

    0 shares
    Share 0 Tweet 0
  • ArbitrationIQ Adds Securities Law Expert and SEC Veteran Teresa Verges to its Consulting Team

    0 shares
    Share 0 Tweet 0
  • New ez1099 2026 The Trusted Solution for On-Time 1099 Filing with Add-On E-File Service

    0 shares
    Share 0 Tweet 0
  • Africa Tech Festival 2026 announces additional high-profile speakers as global business leaders head to Cape Town

    0 shares
    Share 0 Tweet 0
  • Solflare and MoneyGram Ramps Offer Crypto-to-Cash in 170+ Countries and Territories

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler